Exciting Research Insights from Akebia at ASN Kidney Week 2025

Insights from Akebia Therapeutics at ASN Kidney Week 2025

CAMBRIDGE, Mass. — Akebia Therapeutics, Inc. (NASDAQ: AKBA), a dynamic biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, recently shared exciting news about its upcoming presentations during ASN Kidney Week 2025. This significant event for the nephrology community will take place in Houston from November 5-9, 2025, where Akebia will actively engage with healthcare professionals and researchers.

Presenting Innovative Research

One of the highlights of the event will be Dr. Glenn M. Chertow's presentation on the win odds analysis regarding all-cause mortality and hospitalization outcomes from the INNO₂VATE trials, which form part of the Phase 3 clinical development programs focusing on the drug vadadustat. This study evaluates the effectiveness of Vafseo^® (vadadustat) that is already approved in the U.S. for treating anemia in chronic kidney disease (CKD) patients undergoing dialysis for over three months.

Real-World Evidence and Ongoing Studies

In addition to the oral presentation, Akebia will showcase four posters at the event. These will delve deeper into dosing recommendations for vadadustat along with presenting ongoing real-world evidence studies like the VOICE and VOCAL trials. Steven Burke, MD, the Senior Vice President and Chief Research & Development Officer at Akebia, remarked, “Our commitment to collaboration within the nephrology field is unwavering as we aim to uncover further clinical advantages of Vafseo.”

Details of the Oral Presentation

The key oral presentation, titled win-odds analysis of deaths and hospitalization in patients taking Vadadustat or Darbepoetin Alfa for CKD-related anemia undergoing dialysis, is scheduled for November 6, 2025, from 4:30 PM to 6:00 PM in Room 351D of the Convention Center. Dr. Chertow will lead this session, which will highlight vital findings that could impact treatment protocols for patients with chronic kidney disease.

Posters Highlighting Vadadustat Outcomes

Further enriching the conference will be presentations of Akebia-supported posters in the Exhibit Hall. Some key topics include:

• Model-Based Vafseo Starting Dose Recommendations in Dialysis-Dependent CKD Patients — Poster #TH-PO902, to be presented on November 6, from 10:00 AM-12:00 PM CDT.
• Vadadustat Outcomes In-Center Experience (VOICE) Study — Poster #FR-PO0204, on November 7, from 10:00 AM-12:00 PM CDT.
• Consistency of the Estimate of Responsiveness of Vadadustat vs. Darbepoetin — Poster #FR-PO0202, also on November 7, from 10:00 AM-12:00 PM CDT.
• Three Times Weekly In-Center Vadadustat vs. Standard of Care ESA for CKD-Related Anemia (VOCAL) — Poster #INFO10-FR, on November 7, from 10:00 AM-12:00 PM CDT.

About Akebia Therapeutics

Founded in 2007, Akebia Therapeutics, Inc. has established itself as a fully integrated biopharmaceutical company working diligently to advance treatment options for individuals facing kidney-related challenges. With its headquarters in Cambridge, Massachusetts, the company is dedicated to delivering innovative healthcare solutions that drive positive patient outcomes. More information about their research and products can be found on their official website, www.akebia.com.

About Vafseo^® (vadadustat)

Vafseo^® is a daily oral medication that functions as a hypoxia-inducible factor prolyl hydroxylase inhibitor. It works by stimulating the body’s natural production of erythropoietin to enhance hemoglobin and red blood cell levels, effectively managing anemia associated with chronic kidney disease. This treatment has gained approval across 37 countries.

Important Safety Information

For patients considering Vafseo, it’s crucial to be aware of safety information, including potential risks such as increased cardiovascular events and other serious adverse effects. The FDA has emphasized the necessity of using the lowest effective dose to mitigate risks associated with Vafseo, advocating careful monitoring of hemoglobin levels.

Frequently Asked Questions

What is Akebia Therapeutics known for?

Akebia Therapeutics is focused on developing and commercializing therapeutics for patients with kidney disease, particularly through its innovative drug Vafseo.

What are the benefits of Vafseo?

Vafseo is designed to manage anemia in CKD patients by increasing hemoglobin levels and promoting red blood cell production.

When is ASN Kidney Week 2025?

ASN Kidney Week 2025 is scheduled to take place from November 5 to 9 in Houston, Texas.

What type of presentations will Akebia give at the conference?

Akebia will give oral presentations and showcase posters discussing research on vadadustat and its implications for CKD anemia treatment.

How long has Akebia Therapeutics been in operation?

Akebia was founded in 2007 and has been dedicated to advancing treatments for kidney diseases since then.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.